Brofaromine
![]() |
|
Systematic (IUPAC) name | |
---|---|
4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
|
|
Clinical data | |
Routes of administration |
Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 98% |
Biological half-life | 9-14 hours |
Identifiers | |
CAS Number | 63638-91-5 ![]() |
ATC code | none |
PubChem | CID 44571 |
ChemSpider | 40549 ![]() |
UNII | 6WV4B8Q07H ![]() |
KEGG | D02560 ![]() |
ChEMBL | CHEMBL160347 ![]() |
Chemical data | |
Formula | C14H16BrNO2 |
Molar mass | 310.186 g/mol |
|
|
|
|
(verify) |
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.[2]
Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.
Pharmacology[edit]
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.
References[edit]
- ^ US Patent 4210655
- ^ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology. 20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID 10063483. Free full text
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |